GW Pharmaceuticals PLC- (GWPH) Shares Down 5.7%
Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) were down 5.7% during mid-day trading on Wednesday . The company traded as low as $90.65 and last traded at $91.55, with a volume of 1,927,714 shares trading hands. The stock had previously closed at $97.10.
A number of analysts have recently issued reports on GWPH shares. Vetr cut GW Pharmaceuticals PLC- from a “strong-buy” rating to a “hold” rating and set a $73.62 price objective on the stock. in a research report on Thursday, March 31st. Zacks Investment Research cut GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Tuesday, April 19th. Leerink Swann restated a “buy” rating and set a $130.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, June 21st. Morgan Stanley restated a “buy” rating and set a $149.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Friday, June 10th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $147.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Friday, April 1st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $124.92.
The firm’s 50 day moving average price is $90.61 and its 200 day moving average price is $71.41. The company’s market cap is $2.00 billion.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($1.57) by $1.48. During the same period last year, the company posted ($0.03) earnings per share. The company had revenue of $3.81 million for the quarter, compared to analyst estimates of $5.99 million. The business’s revenue for the quarter was down 58.3% on a year-over-year basis. On average, equities analysts anticipate that GW Pharmaceuticals PLC- will post ($3.96) EPS for the current fiscal year.
A hedge fund recently raised its stake in GW Pharmaceuticals PLC- stock. Trexquant Investment LP increased its stake in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 188.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 23,719 shares of the biopharmaceutical company’s stock after buying an additional 15,509 shares during the period. Trexquant Investment LP owned approximately 0.11% of GW Pharmaceuticals PLC- worth $1,647,000 at the end of the most recent reporting period.
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.